NCT07515391

Dapagliflozin Effect on Glucose Variability in Patients Post Bariatric Surgery

• Status: Enrolling By Invitation
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Dasman Diabetes Institute · Academic / Other
• Sex: All
• Age: 21 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the effect of SGLT-2 inhibitors (dapagliflozin) on the blood glucose excursions by a continuous glucose monitoring system, the incidence of hypoglycemia and hyperglycemia and change in glycated hemoglobin (HbA1c) level in people had bariatric surgery with and without type 2 diabetes.

Detailed description

Dapagliflozin is a highly selective sodium-glucose transporter 2 (SGLT2) inhibitor, an approved drug for the treatment of type 2 diabetes. It leads to urinary glucose excretion and a reduction of weight. This results in a reduction of both fasting and postprandial glucose levels. This is reported that the treatment of type 2 diabetes with dapagliflozin carries a low risk of hypoglycaemia and have a beneficial effect on weight and blood pressure. This study hypothesized that bariatric surgery is effective for weight loss. But some patients experience large changes in the blood glucose after meals that lead to hyper and hypoglycaemia and weight regain. This study propose that the use of SGLT-2 inhibitors, which lower glucose and body weight by promoting its renal excretion, will reduce glucose variability in patients after bariatric surgery.

Conditions

• Bariatric Surgery Candidate
• Type2 Diabetes

Interventions

Type	Name	Description
DRUG	Dapagliflozin 10 MG	Dapagliflozin 10 mg drug will be administered in both arms for 12 weeks.

Timeline

• Start date: 2019-10-22
• Primary completion: 2021-05-01
• Completion: 2026-10-22
• First posted: 2026-04-07
• Last updated: 2026-04-07

Locations

1 site across 1 country: Kuwait